Xoft Showcases Multi-Disciplinary Electronic Brachytherapy Cancer Treatment Platform at ASTRO

Xoft Showcases Multi-Disciplinary Electronic Brachytherapy Cancer Treatment
Platform at ASTRO
Clinically Available for Breast, Endometrial and Skin Cancers, the Axxent(R)
Electronic Brachytherapy System Has Been Installed Recently at UCLA, Sloan
Kettering and Beth Israel

CHICAGO, Nov. 2 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(®)
Electronic Brachytherapy, eBx(TM) System, which delivers non-radioactive,
electronic therapy directly to cancer sites with minimal radiation exposure to
surrounding healthy tissue, will showcase its growing suite of oncology
treatment technologies here at the 51st American Society for Radiology and
Oncology (ASTRO) Meeting, November 1-5. Available for treatment of early stage
breast cancer, endometrial cancer, and skin cancer, the Axxent System is also
FDA-cleared for the treatment of other cancers or conditions where radiation
therapy is indicated, including IORT (intra-operative radiation therapy).

The Company also announced that Axxent eBx Systems have been installed
recently at several luminary accounts, including UCLA Medical Center, Memorial
Sloan Kettering Cancer Center, and Beth Israel Medical Center. The systems
are currently being used to clinically treat patients for breast, endometrial
and skin cancer, and will also be used for clinical studies investigating
additional IORT applications.

As a platform technology, the Axxent System addresses a variety of oncological
and non-oncological indications. Designed to deliver non-isotopic therapy
directly to cancer sites during or following surgical removal, the Axxent
System utilizes a proprietary miniaturized X-ray source and robotic controller
and can be used to deliver radiation in minimally shielded therapeutic
settings. Treatment can be performed without the need for a shielded room,
allowing the radiation oncologist and other medical personnel to be present
during treatment delivery which minimizes patient anxiety.

"When Electronic Brachytherapy was first introduced as an electronic,
non-isotopic treatment option for early stage breast cancer, it represented a
paradigm shifting technology," said Michael Klein, president and CEO of Xoft.
"As we have developed additional applications and indications, we are very
pleased with the strong support and rapid adoption of these multi-disciplinary
approaches for use of Electronic Brachytherapy to deliver treatment for
breast, endometrial, skin and other cancers.

"Moving forward, we remain committed to expanding the eBx cancer treatment
platform and are supporting a variety of studies investigating spine,
inter-abdominal and breast applications. As more oncologists and surgeons at
leading institutions such as UCLA, Sloan Kettering, and Beth Israel understand
and adopt this powerful tool, we expect to see studies investigating
additional IORT applications, as well as treatments for pancreatic and other
recurring cancers," added Klein.

About Xoft, Inc.
Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized
X-ray tube technology for the practice of radiation oncology in virtually any
clinical setting, eliminating the need for heavily shielded environments. The
Axxent® treatment platform provides a therapeutic dose of radiation directly
to the region at risk with minimal radiation exposure to surrounding healthy
tissue and without the complex handling, resource logistics and costs
associated with using radioactive isotopes. Xoft aligns with the Nuclear
Regulatory Commission's (NRC) directive to seek alternatives for radioactive
medical isotopes. Commercially available for treatment of early stage breast
cancer, skin cancer and endometrial and rectal indications, the Axxent
Electronic Brachytherapy System is also cleared for use in the treatment of
other cancers or conditions where radiation therapy is indicated. For more
information, visit www.xoftinc.com.

Axxent is a registered trademark and eBx is a trademark of Xoft, Inc.

SOURCE Xoft, Inc.

Chris K. Joseph of Xoft, Inc., +1-510-435-4031, or chris@ckjcomm.com